Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Brainstorm Cell Therapeutics

NASDAQ BCLI
$0.48 -0.02 -3.33%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

21.42M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
20.72M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.03
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
44.25M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
77.29 %

Upcoming events Brainstorm Cell Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Brainstorm Cell Therapeutics

Stock analysis Brainstorm Cell Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.29 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
-4.41 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-0.97 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.03 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
644.58 7.67

Price change Brainstorm Cell Therapeutics per year

2.92$ 17.73$
Min Max

Summary analysis Brainstorm Cell Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Brainstorm Cell Therapeutics

Revenue and net income Brainstorm Cell Therapeutics

All parameters

Stock news Brainstorm Cell Therapeutics

All news
23 February в 18:55

BrainStorm Cell Therapeutics Shares Rise 7.2% on NurOwn Study Request to FDA

26 December 2023 в 19:40

Brainstorm Cell Therapeutics Shares Rise 11% on Patent Approvals

26 December 2023 в 19:35

Brainstorm Cell Therapeutics Shares Rise 11% on Patent Approvals

28 September 2023 в 15:00

Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatment

28 September 2023 в 01:45

FDA Panel Rejects Brainstorm Cell Therapeutics ALS Treatment

28 September 2023 в 01:40

FDA Panel Rejects Brainstorm Cell Therapeutics ALS Treatment

27 March 2023 в 17:20

BrainStorm Cell Therapeutics Shares Rise 13% After FDA Meeting Scheduled

27 March 2023 в 17:20

BrainStorm Cell Therapeutics Shares Rise 13% After FDA Meeting Scheduled

27 March 2023 в 13:26

BrainStorm Cell Therapeutics Gets FDA Meeting to Review BLA for NurOwn

27 March 2023 в 13:20

BrainStorm Cell Therapeutics Gets FDA Meeting to Review BLA for NurOwn

4 January 2023 в 16:01

BrainStorm Cell Therapeutics Names Stacy Lindborg Co-CEO

4 January 2023 в 16:01

BrainStorm Cell Therapeutics Names Stacy Lindborg Co-CEO

10 November 2022 в 17:30

Brainstorm Cell Therapeutics Shares Drop After FDA Refusal for ALS Application

10 November 2022 в 17:25

Brainstorm Cell Therapeutics Shares Drop After FDA Refusal for ALS Application

10 November 2022 в 16:55

Brainstorm Cell Therapeutics's Shares Halted on FDA Refusal for ALS Application

10 November 2022 в 16:55

Brainstorm Cell Therapeutics's Shares Halted on FDA Refusal for ALS Application

17 November 2021 в 16:55

Brainstorm Cell Therapeutics stock price target cut to $8 from $12 at Maxim Group

About company Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Address:
1325 Avenue of Americas, New York, NY, United States, 10019
Company name: Brainstorm Cell Therapeutics
Issuer ticker: BCLI
ISIN: US10501E2019
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2003-08-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.brainstorm-cell.com

On which stock exchange are Brainstorm Cell Therapeutics (BCLI) stocks traded?

Brainstorm Cell Therapeutics (BCLI) stocks are traded on NASDAQ.

What is the ticker of Brainstorm Cell Therapeutics stocks (BCLI)?

The stock ticker of Brainstorm Cell Therapeutics’s stocks or in other words, the code is BCLI. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Brainstorm Cell Therapeutics (BCLI) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Brainstorm Cell Therapeutics (BCLI) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Brainstorm Cell Therapeutics (BCLI) stocks traded?

Brainstorm Cell Therapeutics (BCLI) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Brainstorm Cell Therapeutics (BCLI) stocks today?

The current price of Brainstorm Cell Therapeutics stocks on 16.05.2024 is 0.484 dollars. per share.

What is the dynamics of Brainstorm Cell Therapeutics (BCLI) stocks from the beginning of the year?

Brainstorm Cell Therapeutics (BCLI) quotes have increased by 69.82% from the beginning of the year up to 0.484 dollars. per 1 stocks.

How much did Brainstorm Cell Therapeutics (BCLI) stocks increase in мае 2024?

This month Brainstorm Cell Therapeutics (BCLI) quotes have increased by 11.39% to 0.484 dollars. per share.

How much are Brainstorm Cell Therapeutics (BCLI) stocks worth?

Today, on October, 16.05.2024 Brainstorm Cell Therapeutics’s (BCLI) stocks cost 0.484 dollars..

What is the market capitalization of Brainstorm Cell Therapeutics (BCLI)?

Capitalization is the market value of Brainstorm Cell Therapeutics (BCLI) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 16.05.2024, the market capitalization of Brainstorm Cell Therapeutics (BCLI) is estimated at about 21417876 dollars.